October 1st 2025
A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.
September 26th 2025
September 26th 2025
Use of Inotuzumab for ALL in the Frontline Setting
Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.
Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks
Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.
Poor 2-Year Overall Survival Observed Following HSCT in TP53-Mutant AML
April 29th 2022Patients with TP53-mutant acute myeloid leukemia experienced poor overall survival following treatment with hematopoietic stem cell transplantation, suggesting a need for more careful patient selection, further clinical trial enrollment, and personalized treatment strategies.
Targeting CD117 With JSP191, TBI, and Fludarabine Appears Safe and Efficacious in MDS/AML
April 29th 2022JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.
Ivosidenib and Azacitidine Yield Significant Clinical Benefit Vs Placebo in IDH1-Mutant AML
April 21st 2022Patients with previously untreated IDH1-mutant acute myeloid leukemia experienced significant clinical benefit following treatment with ivosidenib and azacitidine compared with the placebo combination.
Ublituximab/Umbralisib Applications Voluntary Withdrawn for CLL and SLL Indications
April 18th 2022TG Therapeutics made the decision to voluntarily pull the biologics license application and supplemental new drug application for ublituximab/umbralisib in patients with chronic lymphocytic leukemia and small lymphocytic leukemia.
FDA Places Partial Clinical Hold on Phase 1/2 Emavusertib Study in R/R AML, High-Risk MDS
April 6th 2022The phase 1/2a TakeAim Leukemia trial assessing emavusertib alone or with azacitidine or venetoclax in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome has been placed on a partial clinical hold by the FDA.
Analysis Uncovers Mechanisms of Resistance to BTK Inhibitors in R/R CLL
March 2nd 2022New findings indicate that mechanisms of genomic escape seen in covalent and some noncovalent Burton tyrosine kinase inhibitors could be responsible for drug resistance in relapsed/refractory chronic lymphocytic leukemia.
FDA Puts Clinical Hold on Trials Assessing Magrolimab/Azacitidine Combo in AML/MDS
February 2nd 2022Due to an imbalance of investigator-reported unexpected adverse reactions, the FDA placed a partial clinical hold on all trials examining the combination of magrolimab and azacitidine in acute myeloid leukemia and myelodysplastic syndrome.